Talia Biran

Company: Oncolys BioPharma Inc.

Job title: President

Seminars:

Integrating Oncolytic Virotherapy into Immunotherapy Combinations to Overcome Resistance to Immune Checkpoint Inhibitors 3:00 pm

ICIs have been integrated into many tumor types and have become the backbone of many cancer treatments Response to ICI is limited due to ‘cold tumors’ and development of resistance Oncolytic viruses are able to change the tumour microenvironment and may provide a solution for patients who are ICI-refractoryRead more

day: Day Two